2-amino-6-propylpyrimidin-4(3H)-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-amino-6-propylpyrimidin-4(3H)-one
• 英文别名: 6-n-propyl-isocytosine；2-Amino-6-propylpyrimidin-4-ol；2-amino-4-propyl-1H-pyrimidin-6-one
• 化学式: C₇H₁₁N₃O
• mdl: MFCD02091392
• 分子量: 153.184
• InChiKey: FSYKBAWAYYELHH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  67.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-amino-6-propylpyrimidin-4(3H)-one 生成 2-amino-5-bromo-6-propylpyrimidin-4(3H)-one
  参考文献：
  名称：

  摘要：

  DOI：
• 作为产物：
  描述：

  生成 2-amino-6-propylpyrimidin-4(3H)-one
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSÉS CHIMIQUES
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2010120854A1

  公开（公告）日：2010-10-21

  The invention is directed to to substituted indazole derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R1 - R6 and X are defined herein. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of disorders characterized by constitutively activated ACG kinases such as cancer and more specifically leukemia and cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及取代吲唑衍生物。具体而言，本发明涉及根据公式I的化合物：其中R1-R6和X在此定义。本发明的化合物是PDK1的抑制剂，可用于治疗由组成性激活的ACG激酶（如癌症，特别是白血病、乳腺癌、结肠癌和肺癌）引起的疾病。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步涉及使用本发明化合物或包含本发明化合物的药物组合物来抑制PDK1活性和治疗相关疾病的方法。
• Controlling Keto–Enol Tautomerism of Ureidopyrimidinone to Generate a Single-Quadruple AADD-DDAA Dimeric Array
  作者：Jing Zhang、Shuaiwei Qi、Chenyang Zhang、Zengming Fan、Qinwen Ding、Shizhong Mao、Zeyuan Dong

  DOI：10.1021/acs.orglett.0c02644

  日期：2020.9.18

  Units of ureidopyrimidinone (UPy) which dimerize via strong quadruple hydrogen bonding are widely used for the construction of supramolecular systems. This self-complementary system exists in the tautomerism equilibrium of 4[1H]-pyrimidinone dimer and pyrimidin-4-ol dimer, making generated supramolecular assembly systems essentially complicated. In this contribution, a rational but simple design concept

  通过强四重氢键二聚的脲基嘧啶酮（UPy）单元被广泛用于超分子体系的构建。这种自我互补的系统存在于4 [1 H ]-嘧啶酮二聚体和嘧啶丁-4-醇二聚体的互变异构平衡中，使生成的超分子组装系统实质上变得复杂。在此贡献中，描述了一种合理但简单的设计概念，用于通过超分子策略将UPy的自互补四氢键预组织为单四倍DDAA-AADD二聚体阵列。有了这个概念，设计的UPy导数仅形成4 [1 H从单晶X射线衍射和1 H NMR光谱中可以看出，在固态和溶液状态下，通过分子间氢键相互作用的具有酮构型的]-嘧啶酮二聚体。单个DDAA-AADD二聚体阵列提供了确定的非共价驱动力，可用于生成结构清晰的超分子结构，这在超分子化学和材料领域至关重要。
• Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity
  作者：Kamaljit Singh、Kawaljit Singh、Jan Balzarini

  DOI：10.1016/j.ejmech.2013.06.036

  日期：2013.9

  A series of 2-amino-5-bromo-4(3H)-pyrimidinone derivatives bearing different substituents at the C-6 position were synthesized using a highly regioselective lithiation–substitution protocol, and the effect of structural variation at the C-6 position on their antiviral activity in cell culture was evaluated. Although some of the derivatives were found to be active against various virus strains, they

  使用高度区域选择性的锂化-取代方案合成了一系列在 C-6 位置带有不同取代基的 2-amino-5-bromo-4(3 H )-嘧啶酮衍生物，以及 C-6 结构变化的影响评估了它们在细胞培养中的抗病毒活性的位置。尽管发现一些衍生物对各种病毒株具有活性，但它们仅在接近其毒性阈值时才有效。
• Direct synthesis of 5- and 6-substituted 2-aminopyrimidines as potential non-natural nucleobase analogues
  作者：K. Radhakrishnan、Namita Sharma、Lal Mohan Kundu

  DOI：10.1039/c4ra00249k

  日期：——

  A series of 2-aminopyrimidine derivatives, substituted at 5- and 6-positions, were synthesized. The reaction was carried out in a single step by treatment of the corresponding β-ketoester or β-aldehydoester with guanidine hydrochloride in the presence of K2CO3, in a microwave-assisted method without the requirement of solvent. A unique 1 : 1 co-crystal structure was obtained which shows that a 6-p

  合成了一系列5-和6-位取代的2-氨基嘧啶衍生物。该反应通过在K 2 CO 3存在下用盐酸胍处理相应的β-酮酸酯或β-醛二酸酯来一步进行。，不需要溶剂的微波辅助方法。获得独特的1：1共晶体结构，其显示6-苯基-2-氨基嘧啶酮与胞嘧啶形成强的核碱基对，涉及三个氢键。发现该碱基对与天然鸟嘌呤：胞嘧啶（G：C）一样强，表明合成衍生物的潜在应用。此外，我们还报告了第二个共晶体，该晶体以5：1的比例包含5-异丙基-6-甲基-2-氨基嘧啶酮和胞嘧啶，这也显示出很强的碱基配对特性。
• Interferon induction
  申请人：The Upjohn Company

  公开号：US03932617A1

  公开（公告）日：1976-01-13

  A method and therapeutic compositions for inducing interferon formation in vivo. To a host is administered an interferon inducer of the formula: ##SPC1## Wherein X is a member selected from the group consisting of bromo and iodo and Y is a member selected from the group consisting of methyl and ethyl when X is bromo; or Y is a member selected from the group consisting of methyl, ethyl, n-propyl, benzyl and chloro when X is iodo.

  一种诱导体内干扰素形成的方法和治疗组合物。向宿主施用公式的干扰素诱导剂：## SPC1 ## 其中X是从溴和碘组成的组中选择的成员，当X是溴时，Y是从甲基和乙基组成的组中选择的成员；或者Y是从甲基、乙基、正丙基、苄基和氯组成的组中选择的成员，当X是碘时。